Clinical Trial Opportunity for Triple-Negative Breast Cancer
At Cellectar, we are developing precision medicine and personalized cancer treatments using our novel and validated Phospholipid Drug Conjugate (PDC)™ platform which possesses the capacity to deliver a broad array of targeted oncology therapeutics.
Learn About Us
Our unique, cutting-edge tumor-targeting technology provides optionality to selectively deliver a broad array of therapeutic modalities, including radioisotopes, small molecule cytotoxins and biologics to tumor cells by targeting lipid rafts in the plasma membranes of cancer cells. This may result in maximum antitumor activity with minimal off-target effects.
Iopofosine is a first-in-class Phospholipid Drug Conjugate (PDC)™ designed to provide targeted delivery of iodine-131 directly to cancer cells while limiting exposure to healthy cells.
Learn More About Iopofosine